Persons with CKD are commonly hypertensive, and systematic reviews have suggested that the magnitude of BP reduction for a given degree of reduction in dietary sodium intake is magni ed in hypertensive individuals, particularly if usual sodium intake is high.43 CKD populations also have high risk of CV disease and may therefore have a greater absolute risk reduction of such events with dietary sodium reduction, if the relative bene ts in the general population are indeed applicable to CKD. Finally, ACEi and ARBs are commonly used in CKD patients, and post hoc analyses of RCTs demonstrate that low-sodium intake may enhance the effects of these medications on kidney and CV outcomes.70 The Work Group agrees that decreasing dietary sodium intake is likely to also be appropriate in children with CKD, albeit with modi ed targets. Speci c targets are not available from prior studies for children with CKD, but the Work Group believes that adjusting the <2 g (<90 mmol) daily target for body weight in children would be reasonable.71 The Work Group considered the speci c target of sodium intake of <2 g (<90 mmol) daily and found no evidence showing different health bene ts or harms at different sodium intake targets in CKD populations per se. Existing interven- tion studies targeting BP in CKD populations typically targeted <2 g or <2.3 g daily in the low-sodium arms, which are similar to targets recommended for the general popula- Therefore, the present guideline was created in the absence of data suggesting superiority or inferiority of other targets in CKD populations. Further, for concordance across guidelines from various organizations that might facilitate policy decisions, Work Group members agree a target of <2.0 g per day should be recommended for CKD populations. 